descovy comprimé
gilead sciences canada inc - emtricitabine; ténofovir alafénamide (hémifumarate de ténofovir alafénamide) - comprimé - 200mg; 25mg - emtricitabine 200mg; ténofovir alafénamide (hémifumarate de ténofovir alafénamide) 25mg - nucleoside and nucleotide reverse transcriptase inhibitors
stribild comprimé
gilead sciences canada inc - emtricitabine; elvitegravir; fumarate de ténofovir disoproxil; cobicistat - comprimé - 200mg; 150mg; 300mg; 150mg - emtricitabine 200mg; elvitegravir 150mg; fumarate de ténofovir disoproxil 300mg; cobicistat 150mg - hiv integrase inhibitors
tenofovir sandoz 245 mg comprimés pelliculés
sandoz pharmaceuticals ag - tenofovirum disoproxilum - comprimés pelliculés - tenofovirum disoproxilum 245 mg, cellulosum microcristallinum, lactosum monohydricum 232 mg, amylum pregelificatum, crospovidonum, magnesii stearas, Überzug: hypromellosum, macrogolum 400, polysorbatum 80, e 171, pro compresso obducto. - le vih-infektion, l'hépatite b - synthetika
descovy
gilead sciences ireland uc - l'emtricitabine, ténofovir alafenamide - infections au vih - antiviraux à usage systémique - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).
symtuza comprimé
janssen inc - darunavir (Éthanolate de darunavir); cobicistat; emtricitabine; ténofovir alafénamide (hémifumarate de ténofovir alafénamide) - comprimé - 800mg; 150mg; 200mg; 10mg - darunavir (Éthanolate de darunavir) 800mg; cobicistat 150mg; emtricitabine 200mg; ténofovir alafénamide (hémifumarate de ténofovir alafénamide) 10mg - antiretrovirals
biktarvy comprimé
gilead sciences canada inc - bictégravir (bictégravir sodique); emtricitabine; ténofovir alafénamide (hémifumarate de ténofovir alafénamide) - comprimé - 50mg; 200mg; 25mg - bictégravir (bictégravir sodique) 50mg; emtricitabine 200mg; ténofovir alafénamide (hémifumarate de ténofovir alafénamide) 25mg - hiv integrase inhibitors
emtricitabine/tenofovir eg 200 mg - 245 mg compr. pellic.
eg sa-nv - succinate de ténofovir disoproxil 300,6 mg - eq. ténofovir disoproxil 245 mg; emtricitabine 200 mg - comprimé pelliculé - 200 mg - 245 mg - emtricitabine 200 mg; succinate de ténofovir disoproxil 300.6 mg - tenofovir disoproxil and emtricitabine
viread comprimé
gilead sciences canada inc - fumarate de ténofovir disoproxil - comprimé - 300mg - fumarate de ténofovir disoproxil 300mg - nucleoside and nucleotide reverse transcriptase inhibitors
truvada comprimé
gilead sciences canada inc - fumarate de ténofovir disoproxil; emtricitabine - comprimé - 300mg; 200mg - fumarate de ténofovir disoproxil 300mg; emtricitabine 200mg - nucleoside and nucleotide reverse transcriptase inhibitors
emtricitabine/tenofovir disoproxil mylan
mylan pharmaceuticals limited - l'emtricitabine, ténofovir disoproxil maléate - infections au vih - antiviraux à usage systémique - treatment of hiv-1 infection:emtricitabine/tenofovir disoproxil mylan is indicated in antiretroviral combination therapy for the treatment of hiv-1 infected adults (see section 5. emtricitabine/tenofovir disoproxil mylan is also indicated for the treatment of hiv-1 infected adolescents, with nrti resistance or toxicities precluding the use of first line agents, (see sections 4. 2, 4. 4 et 5. pre-exposure prophylaxis (prep):emtricitabine/tenofovir disoproxil mylan is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired hiv-1 infection in adults and adolescents at high risk (see sections 4. 2, 4. 4 et 5.